Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Walmart, pharmacy chains plan to vaccinate young children with COVID shots after authorization

Ruchika Sharma19 Jun 2022 10:00 AM IST

A spokesperson for Walmart said the retail giant and its unit Sam's Club plan to begin vaccinating children as young as 3.

No Generics for AbbVies Rinvoq Until 2037, Analysts See Multi-Billion Dollar Boost

USFDA nod to AbbVie SKYRIZI for Crohn's disease treatment

Ruchika Sharma18 Jun 2022 1:30 PM IST

Crohn's disease is a chronic, systemic disease that manifests as inflammation within the gastrointestinal (or digestive) tract, causing persistent...

Cipla to purchase 21.05 percent stake in Achira Labs to develop affordable medical kits in India

Ruchika Sharma18 Jun 2022 11:22 AM IST

Mumbai: Cipla Limited has announced that the company has signed definitive agreements for acquisition of 21.05% stake (on a fully diluted basis) for...

Roche Itovebi recommended by CHMP for EU approval for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

Roche unveils HPV self sampling solution against cervical cancer

Ruchika Sharma18 Jun 2022 10:00 AM IST

Basel: Roche has announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution...

Roche suffers setback with Alzheimer's treatment

Ruchika Sharma17 Jun 2022 4:36 PM IST

Zurich: Swiss drugmaker Roche said on Thursday its Alzheimer's medicine crenezumab did not slow or prevent cognitive decline in people with a specific...

USFDA concludes inspection at Dr Reddys Labs Srikakulam API facility

LIC shareholding in Dr Reddy's crosses 5 percent mark

Ruchika Sharma17 Jun 2022 3:00 PM IST

This translates into an investment of Rs 1,556.41 crore to buy over 33.3 lakh shares of the pharma company.

Bharat Biotech Chief says we are able to predict pandemic based on changes in virus

Ruchika Sharma17 Jun 2022 2:00 PM IST

Bharat Biotech chairman said that the government should give incentives to potential investors in startups to support their research and innovation.

Reduce gap between second and Covid booster dose from 9 to 6 months, recommends NTAGI

Ruchika Sharma17 Jun 2022 1:15 PM IST

The STSC members were learnt to have also agreed on administration of an additional third dose for renal transplant patients before the precaution...

Covaxin demonstrates robust safety and immunogenicity in children 2-18 years, says Bharat Biotech

Ruchika Sharma17 Jun 2022 12:46 PM IST

COVAXIN is a ready to use liquid vaccine, stored at 2-8°C, with 12 months shelf life and multi dose vial policy.

ResMed to acquire MEDIFOX DAN for USD 1 billion

Ruchika Sharma16 Jun 2022 4:38 PM IST

San Diego: ResMed has announced a definitive agreement to acquire privately held MEDIFOX DAN from Hg, a software and services investor.MEDIFOX DAN's...

Piramal Pharma Solutions expands API capabilities at Digwal site

Ruchika Sharma16 Jun 2022 3:52 PM IST

Mumbai: Piramal Pharma Limited's Pharma Solutions business, a Contract Development and Manufacturing Organization (CDMO), has announced that the...

Pfizer halts COVID drug Paxlovid trial for standard-risk population

Ruchika Sharma16 Jun 2022 2:47 PM IST

The new data, however, showed a 51% relative risk reduction in standard-risk groups, which the company said was not statistically significant.

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok